LABOPHARM ORD
			Symbol			DDSS

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Labopharm Reports Results for Third Quarter Fiscal 2009

2009-11-06 08:35 ET - News Release

    <<
    - Company Advances Plans to Realize the Benefits of Commercialization:
    Streamlines Operations to Focus on Nearer-Term Commercial Opportunities -
    >>

LAVAL, QC, Nov. 6 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its financial results for the third quarter ended September 30, 2009. All figures are in Canadian dollars unless otherwise stated.

"We have made strong progress in recent months towards the commercialization of our novel trazodone formulation in both the United States and Canada," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "In the U.S., with the matters raised in the Food and Drug Administration (FDA)'s complete response letter now resolved, we await the Agency's decision regarding approval of our formulation and continue to prepare for commercialization in the first half of 2010 pending such approval. In Canada, our new drug submission (NDS) has been accepted for review by Health Canada and we look forward to its response during the third quarter of next year."

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.